thank you for registering

“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

QOL improvements were observed among AYA breast cancer survivors after utilizing a mobile health intervention.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Data from the EPIK-B5 study support the use of alpelisib/fulvestrant in previously treated, HR-positive, HER2-negative, PIK3CA-mutated breast cancer.

Key presentations from the 2025 ASH Meeting revealed potential therapeutic advances across leukemia, multiple myeloma, and lymphoma.